

Let's Talk About Targeted Therapies in Non-Small Cell Lung Cancer (NSCLC)

Advanced or Metastatic NSCLC¹

Perform comprehensive genomic profiling for all potentially actionable biomarkers in all patients with advanced or metastatic NSCLC to assess whether they are eligible for targeted therapies before initiating chemotherapy or chemoimmunotherapy.

Chemoimmunotherapy¹

Treat patients with chemoimmunotherapy first line if no actionable biomarkers are found following comprehensive genomic profiling.

Chemotherapy Recommendations¹

If molecular results are pending and you or your patient feel an urgent start to therapy is required, initiate chemotherapy but hold addition of an immune checkpoint inhibitor until all approved targeted therapies have been ruled out.

Targeted Therapy¹

Give precedence to targeted therapy over chemoimmunotherapy when the decision is supported by molecular results. Targeted therapies tend to have better response rates and are better tolerated.

Molecular Biomarker Testing
Current wait time = 2 weeks²

EXIT
Chemo (SOC)
Chemo I/O

CHEMO
CHEMO I/O

Targeted
Therapy
I-66

1. Hendriks LE, et al; ESMO Guidelines Committee. *Ann Oncol*. 2023;34(4):339-357.
2. Lindeman NI, et al. *Arch Pathol Lab Med*. 2018;142(3):321-346.

Scan to watch a
roadmap overview
video designed
for patients.



Lilly